Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Amgen Inc. lost requests for several judgments in Lindis Biotech GmbH’s patent-infringement lawsuit seeking damages for sales of the leukemia treatment Blincyto, according to a federal judge’s mixed ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

BMO Capital analyst Evan Seigerman has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

Investment analysts at Zacks Research lifted their FY2024 earnings per share (EPS) estimates for shares of Amgen in a ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...